Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Prashant Kapoor, Morie A. Gertz, Betsy Laplant, Gabriella C Malave, Eric Wolfe, Eli Muchtar, Mustaqeem A. Siddiqui, Wilson I Gonsalves, Angie R. Emanuel, Taxiarchis Kourelis, Rahma Warsame, David Dingli, Francis K. Buadi, Suzanne R. Hayman, Nelson Leung, Yi L. Hwa, Miriam A. Hobbs, Amie Fonder, Angela Dispenzieri, Martha Q. Lacy, S. Vincent Rajkumar, Shaji K. Kumar
Institution: Mayo Clinic
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2987558218